Topiramate
This anticonvulsant medication is used alone or in combination with other drugs to prevent seizures in epilepsy, and is also approved to prevent migraines and, in combination with phentermine, to treat obesity. It works through multiple mechanisms including blocking sodium channels and enhancing GABA activity in the brain. It can cause cognitive side effects such as difficulty with memory and word-finding, and patients should stay well hydrated to prevent kidney stones.
분자량
339.3630 g/mol
LogP
-0.80
TPSA
124.00 Ų
리핀스키 5의 법칙
통과
치료 영역
약물 분류
작용 기전
Multiple mechanisms: Na+ channel block, GABA enhancement, glutamate inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Multiple mechanisms: Na+ channel block, GABA enhancement, glutamate inhibition.
2D 구조
Cite this structure
Embed this structure
SMILES
CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1
InChI
InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
Molecular Formula
C12H21NO8S
HBD / HBA
1 / 9
회전 가능 결합
3
무거운 원자
22
The combination of topiramate and valproic acid is associated with hyperammonemia and encephalopathy even without hepatotoxicity, representing a unique metabolic interaction.
Topiramate can cause metabolic acidosis through carbonic anhydrase inhibition, which may increase the risk of lactic acidosis in patients on metformin.
Carbamazepine reduces topiramate plasma concentrations by approximately 40% through enzyme induction, potentially impairing seizure control.
Phenytoin reduces topiramate plasma levels via enzyme induction, potentially compromising seizure control when topiramate is added to phenytoin therapy.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
This anticonvulsant medication is used alone or in combination with other drugs to prevent seizures in epilepsy, and is also approved to prevent migraines and, in combination with phentermine, to treat obesity. It works through multiple mechanisms including blocking sodium channels and enhancing GABA activity in the brain. It can cause cognitive side effects such as difficulty with memory and word-finding, and patients should stay well hydrated to prevent kidney stones.
Multiple mechanisms: Na+ channel block, GABA enhancement, glutamate inhibition.
Key pharmacokinetic parameters for Topiramate: Half-life: 21 hours.
Yes, Topiramate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL220492. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284627. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="topiramate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/topiramate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/topiramate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/topiramate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="topiramate"></drugfyi-drug>